clinical trial · NCT05634499

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

HOFFMANN-LA ROCHE →·phase2·active not recruiting·n = 30

Endometrial CancerGiredestrant

brief summary

This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.

started

Jun 27, 2023

primary completion

Aug 28, 2026

completion

Aug 28, 2026

last updated

Jul 10, 2026

official title

A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol